Other · developed by Turn Therapeutics
GX-03 (Hexagen Antimicrobial) is an agent studied in COVID-19. The only source text available describes its dosing as matching that used in Bactroban Nasal studies, and gives no information on its mechanism or composition.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04951349 | Phase 2 | Covid19 | Completed | TTRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Covid19
Updated Nov 1, 2026. Something wrong or missing? Report it on the TTRX page.
See TTRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TTRX catalysts and pipeline →